Total Valuation
Sartorius Stedim Biotech has a market cap or net worth of $323.88B. The enterprise value is $18.30K.
Market Cap$323.88B
Enterprise Value$18.30K
Share Statistics
Sartorius Stedim Biotech has 97,330,410 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding97,330,410
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
Sartorius Stedim Biotech’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 5.44%.
Return on Equity (ROE)0.06
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)5.44%
Return on Capital Employed (ROCE)0.08
Revenue Per Employee289.09K
Profits Per Employee25.87K
Employee Count10,265
Asset Turnover0.37
Inventory Turnover2.35
Valuation Ratios
The current PE Ratio of Sartorius Stedim Biotech is 55.4. Sartorius Stedim Biotech’s PEG ratio is 1.51.
PE Ratio55.4
PS Ratio6.89
PB Ratio5.00
Price to Fair Value5.00
Price to FCF140.53
Price to Operating Cash Flow26.14
PEG Ratio1.51
Income Statement
In the last 12 months, Sartorius Stedim Biotech had revenue of 2.97B and earned 265.60M in profits. Earnings per share was 2.73.
Revenue2.97B
Gross Profit1.35B
Operating Income549.00M
Pretax Income373.20M
Net Income265.60M
EBITDA867.10M
Earnings Per Share (EPS)2.73
Cash Flow
In the last 12 months, operating cash flow was 615.10M and capital expenditures -394.40M, giving a free cash flow of 220.70M billion.
Operating Cash Flow615.10M
Free Cash Flow220.70M
Free Cash Flow per Share2.27
Dividends & Yields
Sartorius Stedim Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Sartorius Stedim Biotech upcoming earnings date is Oct 22, 2026, Before Open (Confirmed).
Last Earnings DateJul 23, 2026
Next Earnings DateOct 22, 2026
Ex-Dividend Date―
Financial Position
Sartorius Stedim Biotech as a current ratio of 1.02, with Debt / Equity ratio of 63.64%
Current Ratio1.02
Quick Ratio0.53
Debt to Market Cap0.12
Net Debt to EBITDA2.51
Interest Coverage Ratio3.60
Taxes
In the past 12 months, Sartorius Stedim Biotech has paid 107.30M in taxes.
Income Tax107.30M
Effective Tax Rate0.29
Enterprise Valuation
Sartorius Stedim Biotech EV to EBITDA ratio is 26.07, with an EV/FCF ratio of 155.48.
EV to Sales7.62
EV to EBITDA26.07
EV to Free Cash Flow155.48
EV to Operating Cash Flow41.97
Balance Sheet
Sartorius Stedim Biotech has $203.90M in cash and marketable securities with $2.40B in debt, giving a net cash position of -$2.20B billion.
Cash & Marketable Securities$203.90M
Total Debt$2.40B
Net Cash-$2.20B
Net Cash Per Share-$22.59
Tangible Book Value Per Share-$3.03
Margins
Gross margin is 44.71%, with operating margin of 18.50%, and net profit margin of 8.95%.
Gross Margin44.71%
Operating Margin18.50%
Pretax Margin12.58%
Net Profit Margin8.95%
EBITDA Margin29.22%
EBIT Margin18.50%
Analyst Forecast
The average price target for Sartorius Stedim Biotech is $4,585.78, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$4,585.78
Price Target Upside― Downside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast1.17%
EPS Growth Forecast25.38%